Key result
Anticancer antibiotics remain a vital component of chemotherapy, though their clinical utility is limited by severe toxicities and drug resistance, prompting ongoing research into novel derivatives.
Anticancer antibiotics remain an important class of chemotherapeutics despite toxicities, and further research into modifications and new scaffolds is needed.
Requires toxicity surveillance in current regimens; extends rationale for novel derivative development.
Anticancer antibiotics have made a successful impact in the field of chemotherapeutics. For most of them, DNA is the molecular target. Some act as DNA intercalators or some prevent DNA repair among other mechanisms of actions, they are seen to have. The major disadvantages of these drugs though are the constant side effects and toxicities. With more focus on discovery of new drugs with newer scaffolds, the urge to discover and modify anticancer antibiotics is being lost. Modifications or even the wider research can yield newer better drugs for clinical use. The review here discusses the current antibiotic therapeutics, newer discoveries in the field as well ideas for future research.
No takes yet. Share an insight, caveat, or question.
Bhattacharya et al. (2015) conducted a review in Cancer. Anticancer antibiotics was evaluated. Anticancer antibiotics remain a vital component of chemotherapy, though their clinical utility is limited by severe toxicities and drug resistance, prompting ongoing research into novel derivatives.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: